<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00070538</url>
  </required_header>
  <id_info>
    <org_study_id>VION-CLI-034</org_study_id>
    <secondary_id>CDR0000334879</secondary_id>
    <secondary_id>MDA-2003-0326</secondary_id>
    <nct_id>NCT00070538</nct_id>
  </id_info>
  <brief_title>VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies</brief_title>
  <official_title>A Phase I Study Of VNP40101M And Cytarabine For Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as VNP40101M and cytarabine, use different ways&#xD;
      to stop cancer cells from dividing so they stop growing or die. Combining more than one drug&#xD;
      may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining VNP40101M with cytarabine in&#xD;
      treating patients who have hematologic malignancies, including myelodysplastic syndrome or&#xD;
      relapsed, refractory, or untreated leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of VP40101M when administered with cytarabine in&#xD;
           patients with hematologic malignancies.&#xD;
&#xD;
        -  Determine the toxic effects of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study of VNP40101M.&#xD;
&#xD;
      Patients receive cytarabine IV over 24 hours on days 1-4 for patients under 65 years of age&#xD;
      OR on days 1-3 for patients 65 years of age and over. Patients also receive VNP40101M IV over&#xD;
      15-60 minutes on day 2. Treatment repeats every 4 weeks for up to 3 courses (in patients with&#xD;
      responding disease) in the absence of disease progression or unacceptable toxicity. Patients&#xD;
      with a continued response may receive additional courses at the discretion of the&#xD;
      investigator.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of VNP40101M until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity. Up to 10 patients may receive treatment at&#xD;
      the MTD.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 25 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>laromustine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of leukemia or myelodysplastic syndromes (MDS) meeting criteria for 1 of the&#xD;
             following:&#xD;
&#xD;
               -  Relapsed or refractory leukemia for which there is no standard therapy&#xD;
                  anticipated to result in a durable remission&#xD;
&#xD;
                    -  Acute myeloid leukemia&#xD;
&#xD;
                    -  Acute lymphocytic leukemia&#xD;
&#xD;
                    -  Chronic myelogenous leukemia&#xD;
&#xD;
                         -  In blast crisis&#xD;
&#xD;
               -  Untreated leukemia and standard therapy is refused&#xD;
&#xD;
               -  Any of the following poor-risk MDS:&#xD;
&#xD;
                    -  Refractory anemia with excess blasts (RAEB)&#xD;
&#xD;
                    -  RAEB in transformation&#xD;
&#xD;
                    -  Chronic myelomonocytic leukemia&#xD;
&#xD;
          -  CNS leukemia allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT or AST no greater than 3 times ULN&#xD;
&#xD;
          -  Chronic hepatitis allowed&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No active heart disease&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No symptomatic coronary artery disease&#xD;
&#xD;
          -  No arrhythmias uncontrolled by medication&#xD;
&#xD;
          -  No uncontrolled congestive heart failure&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No persistent chronic toxic effects from prior chemotherapy greater than grade 1&#xD;
&#xD;
          -  No uncontrolled active infection&#xD;
&#xD;
               -  Infections under control and under active treatment with antibiotics allowed&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 48 hours since prior hydroxyurea&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 2 weeks since prior myelosuppressive cytotoxic agents (in the absence of&#xD;
             rapidly progressing disease)&#xD;
&#xD;
          -  No other concurrent standard or investigational treatment for leukemia&#xD;
&#xD;
          -  No concurrent disulfiram&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Sznol, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vion Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Giles F, Verstovsek S, Thomas D, Gerson S, Cortes J, Faderl S, Ferrajoli A, Ravandi F, Kornblau S, Garcia-Manero G, Jabbour E, O'Brien S, Karsten V, Cahill A, Yee K, Albitar M, Sznol M, Kantarjian H. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res. 2005 Nov 1;11(21):7817-24.</citation>
    <PMID>16278404</PMID>
  </results_reference>
  <results_reference>
    <citation>Giles FJ, Verstovsek S, Cortes J, et al.: Phase I study of VNP40101M (101M) and AraC in patients (pts) with refractory leukemia. [Abstract] J Clin Oncol 22 (14 Suppl): A-6617, 586s, 2004.</citation>
  </results_reference>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>October 3, 2003</study_first_submitted>
  <study_first_submitted_qc>October 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2003</study_first_posted>
  <last_update_submitted>July 17, 2013</last_update_submitted>
  <last_update_submitted_qc>July 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2013</last_update_posted>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>untreated adult acute lymphoblastic leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

